Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
- 1 February 2001
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 28, 4-9
- https://doi.org/10.1016/s0093-7754(01)90297-0
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: